Longitudinal analysis of humoral immunity against SAR individuals up to 8Â months post-symptom onset

Cell Reports Medicine

2, 100290

DOI: 10.1016/j.xcrm.2021.100290

Citation Report

#	Article	IF	Citations
1	Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clinical Hematology International, 2021, 3, 47.	0.7	4
2	Has Convalescent Plasma Therapy Hesitancy Increased COVID-19 Mortality?. South Asian Journal of Cancer, 2021, 10, 42-45.	0.2	1
4	The conundrum of current anti-SARS-CoV-2 vaccines. Cytokine and Growth Factor Reviews, 2021, 60, 46-51.	3.2	6
5	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host and Microbe, 2021, 29, 516-521.e3.	5.1	199
6	Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection. Journal of Infectious Diseases, 2021, 224, 586-594.	1.9	59
7	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses, 2021, 13, 1135.	1.5	17
8	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
12	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. Cell Host and Microbe, 2021, 29, 1137-1150.e6.	5.1	173
13	SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands. Open Forum Infectious Diseases, 2021, 8, ofab378.	0.4	17
16	Know your enemy or find your friend?â€"Induction of IgA at mucosal surfaces. Immunological Reviews, 2021, 303, 83-102.	2.8	25
17	Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	3.9	72
19	SARS-CoV-2 and regular patient treatment â€“ from the use of rapid antigen testing up to treatment specific precaution measures. Head & Face Medicine, 2021, 17, 39.	0.8	3
20	T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cellular and Molecular Immunology, 2021, 18, 2554-2556.	4.8	72
21	Vaccine nationalism and the dynamics and control of SARS-CoV-2. Science, 2021, 373, eabj7364.	6.0	80
22	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 2021, 54, 2143-2158.e15.	6.6	155
23	A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARSâ€CoVâ€2 vaccine. Journal of Medical Virology, 2022, 94, 35-38.	2.5	58
24	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine, 2021, 27, 2012-2024.	15.2	206
25	Symptomatic SARS-COV-2 reinfection: healthcare workers and immunosuppressed individuals at high risk. BMC Infectious Diseases, 2021, 21, 923.	1.3	15

#	Article	IF	Citations
26	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology, 2021, 6, eabj2901.	5.6	67
27	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia, 2022, 36, 476-481.	3.3	25
29	Dynamics of breast milk antibody titer in the six months following SARS-CoV-2 infection. Journal of Clinical Virology, 2021, 142, 104916.	1.6	15
30	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology, 2021, 563, 134-145.	1.1	74
31	A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells. STAR Protocols, 2021, 2, 100851.	0.5	28
32	SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. Epidemiology and Infection, 2021, 149, e153.	1.0	0
33	Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduction and Targeted Therapy, 2021, 6, 346.	7.1	60
34	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nature Microbiology, 2021, 6, 1433-1442.	5.9	94
36	Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins. Journal of Infectious Diseases, 2022, 225, 938-946.	1.9	26
37	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. Scientific Reports, 2021, 11, 21601.	1.6	20
39	Changes in COVID-19 IgM and IgG antibodies in emergency medical technicians (EMTs). American Journal of Emergency Medicine, 2022, 52, 59-63.	0.7	7
40	Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale. Journal of General Virology, 2021, 102, .	1.3	0
41	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. Frontiers in Microbiology, 2021, 12, 789374.	1.5	7
42	Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL). Viruses, 2021, 13, 2336.	1.5	10
43	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection. Viruses, 2021, 13, 2313.	1.5	13
46	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793953.	2.2	25
47	SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Medicine, 2021, 19, 303.	2.3	45
48	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Science Advances, 2021, 7, eabj5629.	4.7	32

#	Article	IF	Citations
49	Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays. Microbiology Spectrum, 2021, 9, e0088621.	1.2	17
50	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host and Microbe, 2022, 30, 97-109.e5.	5.1	83
51	Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes, 2022, 14, 2018899.	4.3	100
52	SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Reports Medicine, 2022, 3, 100510.	3.3	51
53	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Reports, 2022, 38, 110368.	2.9	82
54	Evaluation of Clinical and Immune Responses in Recovered Children with Mild COVID-19. Viruses, 2022, 14, 85.	1.5	6
56	Standardization of a flow cytometry SARS-CoV-2 serologic test. Cytotechnology, 2022, 74, 99-103.	0.7	1
57	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses, 2022, 14, 144.	1.5	12
58	Immunity to SARS-CoV-2 up to 15Âmonths after infection. IScience, 2022, 25, 103743.	1.9	56
59	Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort. Frontiers in Immunology, 2022, 13, 817905.	2.2	10
60	Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115659.	0.8	44
61	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Reports, 2022, 38, 110429.	2.9	50
63	SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells. Viruses, 2022, 14, 5.	1.5	16
64	Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. Journal of Immunology, 2022, 208, 429-443.	0.4	12
65	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nature Communications, 2022, 13, 903.	5.8	7
66	Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells. Pharmaceuticals, 2022, 15, 365.	1.7	2
67	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 2022, 13, 863039.	2.2	10
68	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117

#	Article	IF	Citations
69	Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19. Frontiers in Immunology, 2022, 13, 770982.	2.2	4
71	Protective and pathogenic role of humoral responses in COVID-19. Journal of Microbiology, 2022, 60, 268-275.	1.3	4
72	Study of humoral and cellular immunity in vaccinated with mRNAâ€1273. Apmis, 2022, 130, 261-269.	0.9	3
73	Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection. Viruses, 2022, 14, 532.	1.5	17
74	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naÃ¯ve and previously infected individuals. EBioMedicine, 2022, 78, 103972.	2.7	31
75	HLA-Aâˆ—02:01 restricted TÂcell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Reports, 2021, 37, 110167.	2.9	18
78	Measurement of SARS-CoV-2-Specific Humoral and Cellular Immunity in Coronavirus Disease 2019 Convalescent Health Care Workers in Iraq.. Archives of Razi Institute, 2021, 76, 1255-2127.	0.4	0
79	Opinion Polls and Antibody Response Dynamics of Vaccination with COVID-19 Booster Vaccines. Vaccines, 2022, 10, 647.	2.1	3
80	Covid-19 vaccine immunogenicity in people living with HIV-1. Vaccine, 2022, 40, 3633-3637.	1.7	47
81	Imported SARS-CoV-2 Variants of Concern Drove Spread of Infections across Kenya during the Second Year of the Pandemic. Covid, 2022, 2, 586-598.	0.7	9
82	SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. ELife, 2022, 11, .	2.8	34
84	Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients. Communications Medicine, 2022, 2, .	1.9	2
85	SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults. Sensors & Diagnostics, 2022, 1, 851-866.	1.9	3
86	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	2.2	7
87	Time-dependent contraction of the SARS-CoV-2â€“specific T-cell responses in convalescent individuals. , 2022, , .		0
88	Serology suggests adequate safety measures to protect healthcare workers from COVID-19 in Shiga Prefecture, Japan. PLoS ONE, 2022, 17, e0270334.	1.1	5
89	Temporal associations of B and TÂcell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Reports, 2022, 39, 111013.	2.9	16
91	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. Transfusion Medicine Reviews, 2022, 36, 125-132.	0.9	8

#	Article	IF	Citations
92	Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases, 2023, 76, e350-e359.	2.9	9
93	SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity. Viruses, 2022, 14, 1237.	1.5	10
94	Role of IgM Memory B Cells and Spleen Function in COVID-19. Frontiers in Immunology, 0, 13, .	2.2	6
95	The Impact of Childhood and Parental Vaccination on SARS-CoV-2 Infection Rates in Children. Pediatric Infectious Disease Journal, 2022, 41, 841-845.	1.1	7
96	The humoral response and antibodies against SARS-CoV-2 infection. Nature Immunology, 2022, 23, 1008-1020.	7.0	84
97	Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot. Heliyon, 2022, 8, e09863.	1.4	5
98	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
99	Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine. Journal of Clinical Virology Plus, 2022, 2, 100094.	0.4	2
100	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. International Journal of Molecular Sciences, 2022, 23, 8485.	1.8	6
101	Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice. International Journal of Nanomedicine, 0, Volume 17, 3325-3341.	3.3	4
103	Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients. IScience, 2022, 25, 104990.	1.9	8
104	<scp>COVID</scp>â€19 vaccine humoral response in frequent platelet donors with plateletpheresisâ€associated lymphopenia. Transfusion, 2022, 62, 1779-1790.	0.8	4
105	Two-years antibody responses following SARS-CoV-2 infection in humans: A study protocol. PLoS ONE, 2022, 17, e0272690.	1.1	0
107	A Long Interval Between Priming and Boosting SARS-CoV-2 mRNA Vaccine Doses Enhances B Cell Responses With Limited Impact on T Cell Immunity. SSRN Electronic Journal, 0, , .	0.4	0
108	Adipokines, and not vitamin D, associate with antibody immune responses following dual BNT162b2 vaccination within individuals younger than 60 years. Frontiers in Immunology, 0, 13, .	2.2	8
109	Neutralizing Antibody Responses Among Residents and Staff of Long-Term Care Facilities in the State of New Jersey During the First Wave of the COVID-19 Pandemic. Journal of Community Health, 0, , .	1.9	0
110	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. Cell Reports, 2022, 41, 111554.	2.9	14
111	Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in TÃ¼rkiye: A randomized trial. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	5

#	Article	IF	Citations
112	SARS-CoV-2â€"The Role of Natural Immunity: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 6272.	1.0	12
113	Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. IScience, 2023, 26, 105783.	1.9	4
114	SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions. International Journal of Infectious Diseases, 2023, 126, 155-163.	1.5	4
115	High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. Nature Communications, 2022, 13, .	5.8	12
116	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nature Reviews Immunology, 2023, 23, 381-396.	10.6	61
117	Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. Cell Reports, 2023, 42, 111998.	2.9	15
118	An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. IScience, 2023, 26, 105904.	1.9	9
119	The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Reports Medicine, 2023, 4, 100893.	3.3	16
123	<scp>IgG</scp> antispike persistence and immunophenotype in children infected by <scp>SARSâ€CoV</scp>â€2. Acta Paediatrica, International Journal of Paediatrics, 2023, 112, 805-812.	0.7	0
124	Cross-Reactivity of Antibodies in Intravenous Immunoglobulin Preparation for Protection against SARS-CoV-2. Microorganisms, 2023, 11, 471.	1.6	1
144	Personalized COVID-19 Early Detection Using Wearable Data Based on Self-Reported Records. , 2023, , .		0